Fig. 6

Silencing BATF3 significantly increases sensitivity to cisplatin, while silencing IRF5, ZBTB38 reduces. A, B qRT-PCR and Western blot showing BATF3, IRF5, ZBTB38 knockdown 3 and 4 days after transfection with BATF3-targeting, IRF5-targeting and ZBTB38-targeting siRNAs with cytotoxicity curves of the lung adenocarcinoma cell line A549 and H358 transfected with nontargeting (ctrl) or BATF3-targeting, IRF5-targeting and ZBTB38-targeting siRNAs and treated for 48 h with cisplatin. C Immunohistochemistry for NACT sensitive and insensitive LUAD patients' tumor tissue